References
- Bostrom, P., et al., 2012. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature, 481 (7382), 463–468.
- Colaianni, G., et al., 2014. Irisin enhances osteoblast differentiation in vitro. International journal of endocrinology, 2014, 902186–902188.
- Colaianni, G., et al., 2015. The myokine irisin increases cortical bone mass. Proceedings of the national academy of sciences of the United States of America, 112 (39), 12157–12162.
- Colaianni, G., et al., 2017. Irisin prevents and restores bone loss and muscle atrophy in hind-limb suspended mice. Scientific reports, 7 (1), 2811.
- Farr, J.N., et al., 2016. Identification of senescent cells in the bone microenvironment. Journal of bone and mineral research, 31 (11), 1920–1929.
- Jedrychowski, M.P., et al., 2015. Detection and quantitation of circulating human irisin by tandem mass spectrometry. Cell metabolism, 22 (4), 734–740.
- Kim, H., et al., 2018. Irisin mediates effects on bone and fat via αV integrin receptors. Cell, 175 (7), 1756–1768 e17.
- Kitase, Y., et al., 2018. β-aminoisobutyric acid, l-BAIBA, is a muscle-derived osteocyte survival factor. Cell reports, 22 (6), 1531–1544.
- Lee, P., et al., 2014. Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metabolism, 19 (2), 302–309.
- Neer, R.M., et al., 2001. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. The New England journal of medicine, 344 (19), 1434–1441.
- Qiao, X., et al., 2016. Irisin promotes osteoblast proliferation and differentiation via activating the MAP kinase signaling pathways. Scientific reports, 6 (1), 1–12.
- Robling, A.G., et al., 2008. Mechanical stimulation of bone in vivo reduces osteocyte expression of sost/sclerostin. The journal of biological chemistry, 283 (9), 5866–5875.
- Storlino, G., et al., 2020. Irisin prevents disuse-induced osteocyte apoptosis. Journal of bone and mineral research, 35 (4), 766–775.